Dextromethorphan ( DrugBank: Dextromethorphan )

---

11 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	3
6	Parkinson disease	2
8	Huntington disease	2
13	Multiple sclerosis/Neuromyelitis optica	7
21	Mitochondrial disease	1
46	Malignant rheumatoid arthritis	1
78	Hypopituitarism	1
85	Idiopathic interstitial pneumonia	1
96	Crohn disease	1
97	Ulcerative colitis	1
156	Rett syndrome	5

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03883581 (ClinicalTrials.gov)	July 25, 2019	12/3/2019	Impact of Nuedexta on Bulbar Physiology and Function in ALS	Impact of Nuedexta on Bulbar Physiology and Function in ALS	Amyotrophic Lateral Sclerosis	Drug: dextromethorphan HBr and quinidine sulfate	University of Florida	Holy Cross Hospital, Florida;ALS Association	Completed	18 Years	90 Years	All	28	Phase 1/Phase 2	United States
2	NCT00573443 (ClinicalTrials.gov)	December 2007	13/12/2007	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)	Pseudobulbar Affect (PBA)	Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo	Avanir Pharmaceuticals	INC Research	Completed	18 Years	80 Years	All	326	Phase 3	United States;Argentina;Brazil
3	NCT00021697 (ClinicalTrials.gov)	January 2001	1/8/2001	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS	A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: AVP-923	Avanir Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	100	Phase 3	United States

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01767129 (ClinicalTrials.gov)	July 2013	9/1/2013	Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients	A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.	Dyskinesia;Parkinson's Disease	Drug: AVP-923-45;Drug: Placebo	Avanir Pharmaceuticals	Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	80 Years	All	14	Phase 2	United States;Canada
2	NCT00001365 (ClinicalTrials.gov)	July 1993	3/11/1999	Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System	NMDA Receptor Antagonist Treatment of Neurodegenerative Disease	Neurodegenerative Disease;Parkinson's Disease	Drug: dextromethorphan	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	42	Phase 2	United States

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03854019 (ClinicalTrials.gov)	August 5, 2019	22/2/2019	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease	Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease	Huntington Disease;Irritability	Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: Placebo	The University of Texas Health Science Center, Houston	Cures Within Reach	Recruiting	18 Years	75 Years	All	22	Phase 3	United States
2	NCT00788047 (ClinicalTrials.gov)	November 2008	7/11/2008	A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan	A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects	Huntington Disease;Alzheimer Disease	Drug: Dextromethorphan;Drug: Dimebon + Dextromethorphan	Pfizer	Medivation, Inc.	Completed	18 Years	55 Years	Both	14	Phase 1	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-002178-22-GB (EUCTR)	27/04/2012	29/03/2012	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	Central Neuropathic Pain in Multiple Sclerosis MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A	Avanir Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2	United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
2	EUCTR2011-002178-22-PL (EUCTR)	20/03/2012	25/11/2011	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	Central Neuropathic Pain in Multiple Sclerosis MedDRA version: 15.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A	Avanir Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2	United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
3	EUCTR2011-002178-22-CZ (EUCTR)	08/02/2012	02/11/2011	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	Central Neuropathic Pain in Multiple Sclerosis MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A Product Name: Dextromethorphan/Quinidine Product Code: AVP-923 INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE Other descriptive name: N/A INN or Proposed INN: Quinidine Sulfate Other descriptive name: N/A	Avanir Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2	United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
4	EUCTR2011-002178-22-ES (EUCTR)	26/12/2011	31/10/2011	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis	Central Neuropathic Pain in Multiple Sclerosis MedDRA version: 14.0;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dextrometorfano/Quinidina Product Code: AVP-923 INN or Proposed INN: DEXTROMETORFANO HIDROBROMURO Other descriptive name: N/A INN or Proposed INN: Quinidina sulfato Other descriptive name: N/A Product Name: Dextrometorfano/Quinidina Product Code: AVP-923 INN or Proposed INN: DEXTROMETORFANO HiDROBROMURO Other descriptive name: N/A INN or Proposed INN: Quinidina sulfato Other descriptive name: N/A Product Name: Dextrometorfano/Quinidina Product Code: AVP-923 INN or Proposed INN: DEXTROMETORFANO HIDROBROMURO Other descriptive name: N/A INN or Proposed INN: Quinidina sulfato Other descriptive name: N/A	Avanir Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	400	Phase 2	United States;Czech Republic;Argentina;Poland;Spain;Bulgaria;United Kingdom
5	NCT01462318 (ClinicalTrials.gov)	November 2011	14/7/2011	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab)	Biogen	NULL	Completed	18 Years	65 Years	All	133	Phase 3	United States;Czech Republic;Hungary;Poland;Russian Federation
6	NCT01324232 (ClinicalTrials.gov)	September 2011	23/3/2011	Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis	Central Neuropathic Pain;Multiple Sclerosis	Drug: AVP-923;Drug: Placebo	Avanir Pharmaceuticals	NULL	Completed	18 Years	85 Years	All	200	Phase 2	United States;Argentina;Czechia;Poland;Spain;Czech Republic;Germany;United Kingdom
7	NCT00573443 (ClinicalTrials.gov)	December 2007	13/12/2007	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)	Pseudobulbar Affect (PBA)	Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo	Avanir Pharmaceuticals	INC Research	Completed	18 Years	80 Years	All	326	Phase 3	United States;Argentina;Brazil

Back to top

21. Mitochondrial disease

---

Clinical trials : 39 /  Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Completed	18 Years	65 Years	All	14	Phase 1	United Kingdom

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02368093 (ClinicalTrials.gov)	January 2010	4/2/2015	Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis	A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Dextromethorphan hydrobromide	Taichung Veterans General Hospital	TSH Biopharm Corporation Limited	Completed	18 Years	N/A	All	48	N/A	NULL

78. Hypopituitarism

---

Clinical trials : 492 /  Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00458991 (ClinicalTrials.gov)	June 2001	9/4/2007	rhGH Therapy on Hepatic Drug Metabolism	Recombinant Human Growth Hormone Therapy and Drug Metabolism	Growth Hormone Deficiency, Dwarfism	Drug: Dextromethorphan and Caffeine	University of Louisville	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	4 Years	14 Years	All	9	N/A	United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000037602	2020-01-01	2020-08-29	Clinical observation and study of pirfenidone combined with dextromethorphan on idiopathic pulmonary fibrosis	Clinical observation and study of pirfenidone combined with dextromethorphan on idiopathic pulmonary fibrosis	Interstitial lung disease	1:Dextromethorphan+Pirfenidone;2:Pirfenidone;	Tianjin Medical University General Hospital	NULL	Recruiting	18	75	Both	1:100;2:100;	Phase 4	China

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02760615 (ClinicalTrials.gov)	November 1, 2016	2/5/2016	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study	An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab	Takeda	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 4	United States

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02760615 (ClinicalTrials.gov)	November 1, 2016	2/5/2016	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study	An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease	Colitis, Ulcerative;Crohn Disease	Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab	Takeda	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 4	United States

156. Rett syndrome

---

Clinical trials : 44 /  Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01520363 (ClinicalTrials.gov)	March 2012	25/1/2012	Placebo Controlled Trial of Dextromethorphan in Rett Syndrome	Placebo Controlled Trial of Dextromethorphan in Rett Syndrome	Rett Syndrome	Drug: dextromethorphan;Drug: placebo	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	The Johns Hopkins Institute for Clinical and Translational Research (ICTR)	Completed	1 Year	10 Years	All	57	Phase 2	United States
2	NCT00069550 (ClinicalTrials.gov)	September 2004	29/9/2003	Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	Pathogenesis of Rett Syndrome: Natural History and Treatment	Rett Syndrome	Drug: dextromethorphan;Drug: donepezil hydrochloride	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Recruiting	1 Year	15 Years	Both	90	Phase 3	United States
3	NCT00593957 (ClinicalTrials.gov)	August 2004	4/1/2008	Trial of Dextromethorphan in Rett Syndrome	Trial of Dextromethorphan in Rett Syndrome	Rett Syndrome	Drug: Dextromethorphan	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	NULL	Terminated	2 Years	15 Years	All	38	Phase 2	United States
4	NCT00004807 (ClinicalTrials.gov)	January 1995	24/2/2000	Study of the Pathogenesis of Rett Syndrome		Rett Syndrome	Drug: dextromethorphan;Drug: topiramate;Drug: Donepezil	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Johns Hopkins University	Completed	N/A	45 Years	Both	120	N/A	NULL
5	EUCTR2008-005571-10-NO (EUCTR)		09/01/2009	DEXTROMETORPHAN IN RETT SYNDROME	DEXTROMETORPHAN IN RETT SYNDROME	Rett syndrome (RTT) is a neurological disorder with devastating consequences on the brain. It is characterized by stagnation of development followed by regression, both occurring between age 6 months and 3 years. The clinical picture is dominated by cognitive impairment, loss of communication skills, purposeful hand movements, hand stereotypies, progressive deceleration of head growth, and abnormal locomotion. RTT syndrome presently has no effective therapy other than pallitative care	Product Name: Dextromethorphan	Kennedy Krieger Inst. Johns Hopkins Medicine	NULL	NA			Female: yes Male: no	90	Phase 2	Norway

Back to top